Decentralized Trials Expand Access—but Risk Inequity - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Decentralized Trials Expand Access—but Risk Inequity

  • By

  • Kerri Miller

  • April 15, 2026

  • 4 min

Share

Objective:

To examine the impact of decentralized clinical trials on participant diversity and access, highlighting specific inequities such as underrepresentation of minority groups.

Approach:
    Key Findings:
    • Fewer than 3.5% of participants in the RESOLVE trial self-identified as Hispanic, indicating significant underrepresentation and raising concerns about trial inclusivity.
    • Decentralized trials may trade one set of barriers for another, as they require reliable internet and digital fluency, which are not universally accessible.
    • Remote trials can skew participant demographics towards younger, more educated, and digitally connected individuals, potentially limiting generalizability.
    • Hybrid trial models can improve representation by combining in-person recruitment with remote follow-up, as evidenced by the CASCADE trial.
    Interpretation:

    Decentralized trials have the potential to enhance access but may inadvertently create new forms of exclusion, particularly for underrepresented populations, necessitating a focus on equitable design.

    Limitations:
    • Many remote outcome measures remain unvalidated against traditional in-person assessments, such as those used in the RESOLVE trial.
    • Participation burdens have shifted to participants, who must manage technology and troubleshoot issues independently, which can disproportionately affect certain demographics.
    Conclusion:

    As remote trials become more prevalent, ensuring diverse representation should be a primary design consideration, with hybrid models being a viable solution to mitigate exclusion.

    Sources:

Original Source(s)

Related Content